Nipah Virus – Who Knows?

 

  1. Nipah virus is a virus found in animals but can also affect humans.
  2. People with infection can develop a fever and symptoms involving the brain (such as headache or confusion) and/or the lungs (such as difficulty breathing or cough).
  3. Cases of Nipah virus infection were first reported in 1998 and since then have been reported in Bangladesh, India, Malaysia, the Philippines, and Singapore. The case fatality rate is estimated at 40% to 75%.
  4. Fruit bats of the Pteropodidae family are the natural host of the Nipah virus. Nipah virus usually transmits from infected bats and other animals to humans and can also be transmitted directly between people.
  5. There is currently no treatment or vaccine available for the Nipah virus; however, several candidate products are under development. Early intensive supportive care can improve survival.

Overview

Nipah virus is a zoonotic virus, usually transmitted from animals to humans, but can also be transmitted through contaminated food or directly between people.

Nipah virus was first identified in 1998 during an outbreak among pig farmers in Malaysia. In 1999, an outbreak was reported in Singapore following the importation of sick pigs from Malaysia. No new outbreaks have been reported from Malaysia or Singapore since 1999. In 2001, Nipah virus infection outbreaks were detected in India and Bangladesh. In Bangladesh, outbreaks have been reported almost every year since. In India, outbreaks are periodically reported in several parts of the country, including the latest one in 2026.

In 2014, an outbreak was reported in the Philippines, with no new cases since then.

Transmission

Fruit bats from the Pteropodidae family are considered the natural host of the Nipah virus and are present in different parts of Asia and in Australia. African fruit bats of the genus Eidolon, family Pteropodidae, have been found to have antibodies against Nipah and Hendra viruses, indicating that these viruses might also be present within the geographic distribution of Pteropodidae bats in Africa.

Infection with the Nipah virus does not appear to cause disease in fruit bats.

Transmission of the virus to humans can occur from direct contact with infected animals like bats, pigs, or horses and by consuming fruits or fruit products, such as raw date palm juice, contaminated by infected fruit bats. The virus can also cause severe disease in farming animals such as pigs.  

Nipah virus can also spread between people. It has been reported in health-care settings and among family and caregivers of sick people through close contact. In health facilities, the risk of spread can increase in overcrowded, poorly ventilated hospital environments with inadequate implementation of infection prevention and control measures (such as the use of personal protective equipment, cleaning and disinfection, and hand hygiene).

Signs and symptoms 

The incubation period—that is, the time from infection to the onset of symptoms—ranges from 3 to 14 days. In some rare cases, incubation of up to 45 days has been reported.

For some people, Nipah virus infection may be asymptomatic. However, most people develop a fever and symptoms involving the brain (such as headache or confusion) and/or the lungs (such as difficulty breathing or cough). Other organs can also be affected. Other frequent symptoms include chills, fatigue, drowsiness, dizziness, vomiting, and diarrhea.

Severe disease can occur in any patient but is particularly associated with people presenting with neurological symptoms, with progression to brain swelling (encephalitis) and, frequently, death. Careful supportive care and monitoring during this period are critical.

Most people who survive make a full recovery, but long-term neurologic conditions have been reported in approximately 1 in 5 people who recovered from the disease.

Diagnosis

It is difficult to distinguish Nipah from other infectious diseases or other causes of encephalitis or pneumonia without laboratory testing. The main diagnostic test is real-time polymerase chain reaction (RT-PCR) of respiratory samples, blood, or cerebrospinal fluid (a spinal tap). Blood antibody detection via enzyme-linked immunosorbent assay (ELISA) may also be used. 

Samples collected from patients are a biohazard risk. Laboratory testing on non-inactivated samples should be conducted under maximum biological containment conditions.  

Samples taken from people and animals with suspected Nipah virus infection should be handled by trained staff working in suitably equipped laboratories.

Treatment

While there are no specific treatments for Nipah, early diagnosis will promote early supportive care. For all severe viral infections, high-quality supportive medical care can prevent deaths and includes:

  • identifying any complications (brain swelling, pneumonia, other organ damage);
  • personalizing treatment to account for patients’ other health conditions;
  • treating with oxygen when required;
  • applying specific organ support therapies as needed (such as ventilation and renal dialysis); and
  • ensuring adequate rehydration and nutrition with frequent monitoring.

There are currently no approved drugs or vaccines for Nipah virus infection.  A range of candidate products is under different stages of development.  

Prevention

Reducing the risk of infection in people

Raising awareness of the risk factors for infection and measures people can take to protect themselves and prevent transmission is critical. WHO recommends taking measures as noted below.

  • Reducing the risk of bat-to-human transmission

Efforts to prevent transmission should first focus on decreasing bat access to date palm sap and other fresh food products. Keeping bats away from sap collection sites by using protective coverings may be helpful. Freshly collected date palm juice should be boiled, and fruits should be thoroughly washed and peeled before consumption. Fruits with any sign of bat bites should be discarded.

  • Reducing the risk of animal-to-human transmission

Gloves and other protective clothing should be worn while handling sick animals such as pigs or horses and during slaughtering and culling procedures. In areas where the virus is present, when establishing new pig farms, considerations should be given to the presence of fruit bats in the area, and in general, pig feed and pig sheds should be protected against bats when feasible.

  • Controlling Nipah virus in pigs

In past outbreaks of Nipah involving pig farms, several measures were implemented to reduce transmission, including routine and thorough cleaning and disinfection of farms; quarantining animal premises in the case of suspected cases; culling of infected animals, with close supervision of burial or incineration of carcasses; and restricting or banning the movement of animals from infected farms to other areas.

  • Reducing the risk of human-to-human transmission

People experiencing Nipah-like symptoms should be referred to a health facility, as early supportive care is key in the absence of licensed treatment. Close unprotected physical contact with sick people should be avoided. Regular hand washing should be carried out after caring for or visiting sick people, along with other preventive measures.

Controlling infection in health-care settings

WHO advises health-care workers to implement standard precautions for infection prevention and control at all times for all patients:

  • Suspected or confirmed cases of Nipah virus infection should be placed in a single-patient room.
  • When caring for patients, WHO advises the use of contact and droplet precautions, including a well-fitting medical mask, eye protection, a fluid-resistant gown, and examination gloves.
  • Airborne precautions should be implemented during aerosol-generating procedures, including placing the patient in an airborne-infection isolation room and using a fit-tested filtering facepiece respirator instead of a medical mask; and
  • For family members and caregivers visiting patients with suspected or confirmed Nipah virus, similar precautions should be applied.  

WHO continues to monitor any upcoming new evidence to ensure recommendations remain up-to-date.

WHO Response

WHO works closely with at-risk countries and partners to strengthen preparedness for and response to outbreaks of Nipah virus infection by providing technical guidance and supporting surveillance activities, clinical management, laboratory services, infection prevention and control measures, logistics, training, and community engagement.

Generation of further knowledge, including for diagnostics and therapeutics, and exchange of expertise across countries and partners, including through research activities, is critical to contribute to the management of Nipah virus infection and to reduce mortality and mitigate human-to-human transmission in health-care facilities.